Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
12 papers
Recent·Most cited
N. Paran, Y. Yahalom-Ronen, O. Shifman, S. Lazar, R. Ben-Ami, M. Yakubovsky, I. Levy, A. Wieder Feinsod, S. Amit, M. Katzir, N. Carmi Oren, A. Levcovich, M. Hershman-Sarafov, A. Paz, R. Thomas, , T. Israely
The paper correlates Monkeypox DNA content with virus infectivity in clinical samples and defines a PCR threshold for non-infectious virus.
bioRxiv · Aug 2, 2022 · PreprintMicrobiology
T. Fisher, A. Gluck, K. Narayanan, M. Kuroda, A. Nachshon, J. C Hsu, P. J Halfmann, Y. Yahalom-Ronen, Y. Finkel, M. Schwartz, S. Weiss, C.-T. K Tseng, T. Israely, N. Paran, Y. Kawaoka, , N. Stern-Ginossar
This study investigates the role of SARS-CoV-2 nsp1 in host shutoff and immune evasion, finding it inhibits translation and induces mRNA degradation, and is critical for counteracting the IFN response.
bioRxiv · Mar 14, 2022Microbiology
S. Melamed, B. Politi, E. Grauer, H. Achdout, M. Aftalion, D. Gur, H. Tamir, Y. Yahalom-Ronen, S. Maimon, E. Yitzhak, S. Weiss, A. Rosner, N. Erez, S. Yitzhaki, S. C. Shapira, , T. Israely
This study uses group activity monitoring in hamsters and mice to assess SARS-CoV-2 infection, convalescence, and vaccine efficacy.
Frontiers in Bioengineering and Biotechnology · Oct 1, 2021Peer-reviewedImmunology
M. Israeli, Y. Finkel, Y. Yahalom-Rone, N. Paran, T. Chitlaru, O. Israeli, I. Cohen-Gihon, M. Aftalion, R. Falach, U. Elia, I. Nemet, L. Kliker, M. Mandelboim, A. Beth-Din, T. Israely, , A. Bercovich-Kinori
This study uses CRISPR screens to identify host factors critical for SARS-CoV-2 infection, finding GATA6 as a key modulator of ACE2 expression and viral entry.
bioRxiv · Jul 19, 2021 · PreprintMicrobiology
N. Madar-Balakirski, A. Rosner, S. Melamed, B. Politi, M. Steiner, H. Tamir, Y. Yahalom Ronen, E. Bar-David, A. Ben-Shmuel, A. Sittner, I. Glinert, S. Weiss, E. Bar-Haim, H. Cohen, U. Elia, , H. Marcus
This study evaluates the safety, immunogenicity, and efficacy of an rVSV-ΔG-SARS-CoV-2-S vaccine in multiple animal species, finding no adverse effects and a robust immune response.
bioRxiv · Jul 6, 2021Pharmacology & Toxicology
E. Makdasi, A. Zvi, R. Alcalay, T. Noy-Porat, E. Peretz, A. Mechaly, Y. Levy, E. Epstein, T. Chitlaru, A. Tennenhouse, M. Aftalion, D. Gur, N. Paran, H. Tamir, O. Zimhony, , R. Rosenfeld
This study evaluates the neutralization potency of four SARS-CoV-2 mAbs against spike mutations and two variants of concern, finding that MD65 and BL6 retain effectiveness against B.1.1.7 and B.1.351.
bioRxiv · Apr 1, 2021Immunology
Y. Finkel, A. Gluck, R. Winkler, A. Nachshon, O. Mizrahi, Y. Lubelsky, B. Zuckerman, B. Slobodin, Y. Yahalom-Ronen, H. Tamir, I. Ulitsky, T. Israely, N. Paran, M. Schwartz, N. Stern-Ginossar
This study identifies how SARS-CoV-2 suppresses host protein synthesis through global translation reduction, mRNA degradation, and impaired translation of immune-related transcripts.
bioRxiv · Nov 25, 2020Microbiology
Y. Finkel, O. Mizrahi, A. Nachshon, S. Weingarten-Gabbay, D. Morgenstern, Y. Yahalom-Ronen, H. Tamir, H. Achdout, D. Stein, O. Israeli, A. Beth-Din, S. Melamed, S. Weiss, T. Isrealy, N. Paran, , N. Stern-Ginossar
This study maps the full coding capacity of SARS-CoV-2 using ribosome profiling, identifying 23 novel translated ORFs and revealing viral translation dominance over host translation.
Nature · Sep 9, 2020Peer-reviewedMicrobiology
Y. Yahalom-Ronen, H. Tamir, S. Melamed, B. Politi, O. Shifman, H. Achdout, E. B. Vitner, O. Israeli, E. Milrot, D. Stein, I. Cohen-Gihon, S. Lazar, H. Gutman, I. Glinert, L. Cherry, , T. Israely
This study develops a recombinant VSV-ΔG-spike vaccine that provides single-dose protection against SARS-CoV-2 in hamsters by inducing neutralizing antibodies and preventing lung pathology.
bioRxiv · Jun 18, 2020Microbiology
O. Israeli, A. Beth-Din, N. Paran, D. Stein, S. Lazar, S. Weiss, E. Milrot, Y. Atiya-Nasagi, S. Yitzhaki, O. Laskar, O. Schuster
The paper compares RT-qPCR efficacy with and without RNA extraction for SARS-CoV-2 detection, finding that extraction is advantageous but a direct no-buffer approach can identify up to 70% of clinical specimens.
bioRxiv · Jun 10, 2020Microbiology
T. Noy-Porat, E. Makdasi, R. Alcalay, A. Mechaly, Y. Levy, A. Bercovich-Kinori, A. Zauberman, H. Tamir, Y. Yahalom-Ronen, M. Israeli, E. Epstein, H. Achdout, S. Melamed, T. Chitlaru, S. Weiss, , R. Rosenfeld
This paper isolates and characterizes a panel of human neutralizing monoclonal antibodies targeting SARS-CoV-2 spike at multiple epitopes, suggesting their potential for combined post-exposure therapy.
bioRxiv · May 20, 2020Immunology
E. B. Vitner, R. Avraham, H. Achdout, H. Tamir, A. Agami, L. Cherry, Y. Yahalom-Ronen, B. Politi, N. Erez, S. Melamed, N. Paran, T. Israely
The study evaluates two GCS inhibitors for antiviral activity against four enveloped RNA viruses, including SARS-CoV-2, showing broad-spectrum efficacy and improved survival in infected mice.
bioRxiv · May 18, 2020 · PreprintMicrobiology